Author Bio
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.
Follow @keithspeights
Millions of Americans have already received two COVID-19 vaccine shots. However, there s a possibility that a third booster dose will be needed. In this
Motley Fool Live video
recorded on May 17, 2021, Healthcare and Cannabis Bureau Chief Corinne Cardina and Motley Fool contributor Keith Speights discuss when we ll know if a booster shot will be required or not.
Corinne Cardina: Let s talk about the future of booster shots speaking of making a lot of money in the long run. What should investors know? What s the latest in terms of when are we going to know when we ll need more shots, whether it s a year out. Tell me about that.
Author Bio
Taylor Carmichael is a former attorney and filmmaker. He s the author of a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool.
In December, the Food and Drug Administration (FDA) gave emergency use authorizations (EUA) to the mRNA vaccines from
Pfizer (NYSE:PFE). Since then, the two companies have seized the lion share of the vaccine market in the U.S.
Meanwhile, the
Novavax (NASDAQ:NVAX) vaccine has been delayed, and the company now hopes that it will receive an EUA in July. Will there be any vaccine market left for the biotech upstart? In this clip from
Over the past 12 months, shares of the
Horizons Marijuana Life Sciences ETF (OTC:HMLSF) have shot up over 100%. Meanwhile, pick-and-shovel play
GrowGeneration (NASDAQ:GRWG) returned 1,370% to investors and Illinois-based pure-play stock,
Green Thumb Industries (OTC:GTBIF), rode increased demand in its home state to over 300% gains in its share price. It doesn t take much research to figure out that cannabis is booming no matter the fact that the drug is not yet legal at the federal level.
In a period of rapid change, it s difficult to know exactly what s ahead for the industry and its players. Dr. Chanda Macias is a medical cannabis advocate, researcher, and dispensary owner. The cannabis pro joined Olivia Zitkus and Corinne Cardina on a
Ever wonder why
Trulieve Cannabis (OTC:TCNNF) has focused most of its resources on dispensaries in Florida, while
Green Thumb Industries (OTC:GTBIF) chose to vertically integrate and cement its foothold on the marijuana market in its home state of Illinois? The answer has to do with the federal illegal status of cannabis, and the fact that states have different rules and regulations surrounding recreational and medical uses of the drug. Horizontal integration and running cannabis operations in various states can be a perilous (and expensive) venture.
Dr. Chanda Macias is a medical cannabis advocate, research, and dispensary owner. She joined Olivia Zitkus and Corinne Cardina of the Healthcare and Cannabis Bureau on a
Are
Aurora Cannabis (NYSE:ACB) cost problems too big for the business to ever reach profitability? Is a pick-and-shovel play like
GrowGeneration (NASDAQ:GRWG) really going to give me access to all of the growth potential of the cannabis industry? For new and experienced investors alike, picking pot stocks comes with new sets of challenging questions like these.
Before you start scooping up shares of companies in the red hot sector, it s important to do your research. Dr. Chanda Macias is a medical cannabis advocate, research, and dispensary owner. Dr. Macias joined Olivia Zitkus and Corinne Cardina of the Healthcare and Cannabis Bureau on a